- First Online:
- 93 Downloads
Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.
There is ample evidence that valsartan/hydrochlorothiazide is an effective fixed-dose combination antihypertensive agent. However, efficacy and tolerability data pertaining to the 320mg dose of valsartan in the combination are currently relatively few. There is also some evidence of potential benefits associated with the relatively favourable tolerability profile of the combination, the low occurrence of new-onset diabetes mellitus versus amlodipine and the valsartan-associated improvements in cardiac and endothelial function.
Valsartan is a selective antagonist of the angiotensin II type 1 receptor. This drug has established antihypertensive effects and is associated with improvements in cardiac function (reduced left ventricular mass), endothelial function (improved basal nitric oxide availability, reduced formation of reactive oxygen species, reduced C-reactive protein levels) and lipid profiles.
Hydrochlorothiazide is a thiazide diuretic which inhibits Na-Cl transport in the kidney and reduces plasma volume. It has been associated with improvements in cardiac output, mean arterial pressure, stroke volume, heart rate and total peripheral resistance in patients with hypertension. It has also been linked with dyslipidaemia, hyperglycaemia and increased risk of developing type 2 diabetes mellitus in some patients, and it may increase levels of some inflammatory biomarkers.
Coadministration of valsartan and hydrochlorothiazide does not have a clinically relevant pharmacokinetic effect on either drug. Plasma concentrations of both components increase dose-proportionally, with peak concentrations reached in 2–5 hours. The elimination half-life of the components ranges from 2.5 to 19 hours, mainly because of variability in hydrochlorothiazide values. Clearance is 2.2 L/h for valsartan and 20–22 L/h for hydrochlorothiazide. Excretion of valsartan is mainly faecal and that of hydrochlorothiazide is mainly renal. While the systemic clearance of hydrochlorothiazide is decreased in older patients, the effects of age on valsartan pharmacokinetics are not considered clinically significant. Exposure to hydrochlorothiazide is increased in patients with renal dysfunction and exposure to valsartan is increased in patients with hepatic dysfunction.
The superior antihypertensive efficacy of once-daily valsartan 80–320mg plus hydrochlorothiazide 12.5 or 25mg over the individual components has been demonstrated in well designed trials in patients with hypertension unresponsive to monotherapy or with moderate to severe hypertension.
In the only trial investigating comparative clinical cardiovascular outcomes, valsartan-and amlodipine-based therapy regimens had similar results for the primary efficacy parameter (total cardiac morbidity and mortality 10.6% vs 10.4%), despite not achieving the prespecified equivalent reduction in blood pressure (BP). Patients (aged ≥50 years) at high cardiovascular risk received increased dosages of monotherapy and then additional hydrochlorothiazide as required for a mean of 4.2 years. BP reduction and occurrence of myocardial infarction favoured amlodipine-based therapy, while the rate of new-onset diabetes mellitus favoured valsartan-based therapy. In contrast, equivalent BP reduction was seen in a 6-month comparison of valsartan-based and amlodipine-based therapy in elderly patients with moderate to severe isolated systolic hypertension.
Valsartan/hydrochlorothiazide recipients had similar BP reductions to those in patients receiving amlodipine monotherapy in two double-blind trials; a significantly greater reduction in systolic BP was seen with the higher hydrochlorothiazide dose in another double-blind trial. One single-blind trial indicated superior systolic/diastolic BP reductions with the combination. Noninferiority for valsartan/hydrochlorothiazide versus amlodipine monotherapy has been demonstrated in Black African-American patients with mild to moderate hypertension.
There are preliminary indications that valsartan/hydrochlorothiazide has generally similar antihypertensive efficacy to that of other angiotensin receptor blocker/hydrochlorothiazide combinations.
Valsartan/hydrochlorothiazide is well tolerated. Adverse events (most commonly dizziness, headache and fatigue) are generally mild and transient. Serious adverse events that have rarely been associated with the combination include orthostatic hypotension, syncope, angioneurotic oedema, angina pectoris and atrial fibrillation. The tolerability profile of the combination was superior to that of lisinopril/hydrochlorothiazide (similar efficacy profile). Hypokalaemia occurs less often with the valsartan/hydrochlorothiazide combination than with hydrochlorothiazide monotherapy or amlodipine/hydrochlorothiazide.
- 10.Novartis Pharmaceuticals UK Ltd. Co-Diovan 80/12.5 mg, 160/ 12.5 mg/160/25 mg tablets; UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Apr 26]
- 16.Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004 Jun 2; 43(11): 2116–23PubMedCrossRefGoogle Scholar
- 22.Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST Study. Clin Ther 2005 May; 27(5): 578–87PubMedCrossRefGoogle Scholar
- 27.Ohbayashi Y, Tsutamoto T, Sakaguchi T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003 Dec; 42 (Suppl. 1): S71–4PubMedCrossRefGoogle Scholar
- 38.Weisser B, Vetter H, Mengden T. Decreased blood pressure, pulse pressure and heart rate under treatment with valsartan alone or combined with hydrochlorothiazide: results of an open trial in 11447 hypertensives [in German]. Dtsch Med Wochenschr 2003 Mar 14; 128(11): 541–4PubMedCrossRefGoogle Scholar
- 39.Malacco E, Santonastaso M, Vari NA, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 2004 Jun; 26(6): 855–65PubMedCrossRefGoogle Scholar
- 42.Novartis Pharmaceuticals Corporation. Diovan HCT®valsartan and hydrochlorothiazide, USP; combination tablets 80mg/ 12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, 320mg/25mg; US prescribing information. East Hanover (NJ): Novartis, 2006Google Scholar
- 43.Novartis Pharmaceuticals Canada Inc. Diovan-HCT (valsartan and hydrochlorothiazide) tablets, 80mg/12.5mg, 160mg/ 12.5mg, and 160mg/25mg; Canadian prescribing information. Dorval, Quebec: Novartis, 2004Google Scholar
- 45.Taeschner W, Vozeh S. Appendix A: pharmacokinetic drug data. In: Speight TM, Holford NHG, editors. Avery’s Drug Treatment. 4th ed. Auckland: Adis International Limited, 1997: 1629–64Google Scholar
- 47.Kalbag J, Prasad P, Redalieu E, et al. Plasma concentrations and antihypertensive effect of 10 to 160 mg doses of valsartan (VAL) in hypertensive patients [abstract no. PPDM 8140]. Pharm Res 1994; 11 (10 Suppl.): S367Google Scholar
- 55.Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998 Dec; 12(12): 861–6Google Scholar
- 57.Hedner T, Reimund B, Le Breton S, et al. Valsartan and hydrochlorothiazide combination therapy (320/12.5 mg and 320/25 mg) provides effective blood pressure control in hypertensive patients inadequately controlled by monotherapy. American Society of Hypertension 21 st annual scientific meeting and exposition, May 16–20 2006, New York; Abstract no. P-165 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
- 58.Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005 Jul; 27(7): 1013–21PubMedCrossRefGoogle Scholar
- 60.Pool J, Glazer R, Weinberger M, et al. Treatment with valsartan and hydrochlorothiazide alone and in combination at doses up to 320/25 mg provides effective blood pressure control in hypertensive patients. American Society of Hypertension 21st annual scientific meeting and exposition, May 16–20 2006, New York; Abstract no. P-179 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
- 65.Ruilope LM, Heintz D, Brandao AA, et al. 24-hour ambulatory blood-pressure effects of valsartan & hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study. Blood Press Monit 2005 Apr; 10(2): 85–91PubMedCrossRefGoogle Scholar
- 67.Pool J, Glazer R, Graff A, et al. Long-term combination treatment with valsartan and hydrochlorothiazide (320/12.5 mg and 320/25 mg) provides effective blood pressure control and is well-tolerated in hypertensive patients. American Society of Hypertension 21st annual scientific meeting and exposition, May 16–20 2006, New York; Abstract no. P-180 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
- 68.Weir MR, Aknay N, Purkayastha D, et al. Antihypertensive efficacy of valsartan and valsartan/HCTZ in elderly hypertensives: exploratory analyses of nine clinical trials. American Society of Hypertension 21st annual scientific meeting and exposition, May 16–20 2006, New York; Abstract no. P-2310 [online]. Available from URL: http://www.ash-us.org [Accessed 2006 May 17]
- 69.Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison of the antihypertensive effects of the candesartan 8 mg-hydrochlorothiazide 12.5 mg combination (C8+H) vs the valsartan 80 mg-hydrochlorothiazide 12.5 mg combination (V80+H) in patients with essential hypertension resistant to monotherapy [abstract no. P2.367]. J Hypertens 2004 Jun; 22 (Suppl. 2): S254–5Google Scholar
- 71.White W, Punzi H, Neutel J, et al. Telmisartan plus hydrochlorothiazide (80/25 mg) has a greater antihypertensive effect than valsartan plus hydrochlorothiazide (160/25 mg) in patients with stage 1 and 2 hypertension [abstract no. P254]. Am J Hypertens 2005 May; 18 (5 pt 2): 97A [plus poster presented at the 20th Annual Scientific Meeting of the American Society of Hypertension; 2005 Dec 10–13; San Fransisco (CA)]Google Scholar
- 73.Palatini P, Mugellini A, Spagnuolo V, et al. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit 2004 Apr; 9(2): 91–7PubMedCrossRefGoogle Scholar
- 74.Malacco E, Palatini P, Val-Combo Investigators. The efficacy and tolerability of valsartan-based versus lisinopril-based treatment in patients with mild to moderate hypertension: the Val-Combo study [abstract no. P728]. J Hypertens 2004 Feb; 22 (Suppl. 1): 197SGoogle Scholar
- 79.Chalmers J, Guidelines Sub-Committee. 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. Blood Press 1999; 8 (Suppl.1): 9–43Google Scholar
- 90.Goodman R, Lanese JW, Singson CR, et al. Symptom assessment and quality of life in hypertensive patients following modification of antihypertensive therapy to a regimen containing valsartan. J Outcomes Res 2004; 8: 1–14Google Scholar